Design and development of novel bioadhesive niosomal formulation for thetranscorneal delivery of anti-infective agent: In-vitro and ex-vivo investigations Yahaya Zubairu, Lalit Mohan Neg
Trang 1Design and development of novel bioadhesive niosomal formulation for the
transcorneal delivery of anti-infective agent: In-vitro and ex-vivo investigations
Yahaya Zubairu, Lalit Mohan Negi, Zeenat Iqbal, Sushama Talegaonkar
DOI: 10.1016/j.ajps.2015.02.001
Reference: AJPS 124
To appear in: Asian Journal of Pharmaceutical Sciences
Received Date: 23 July 2014
Revised Date: 8 February 2015
Accepted Date: 16 February 2015
Please cite this article as: Zubairu Y, Negi LM, Iqbal Z, Talegaonkar S, Design and development of novel bioadhesive niosomal formulation for the transcorneal delivery of anti-infective agent: In-vitro and ex-vivo
investigations, Asian Journal of Pharmaceutical Sciences (2015), doi: 10.1016/j.ajps.2015.02.001.
This is a PDF file of an unedited manuscript that has been accepted for publication As a service to our customers we are providing this early version of the manuscript The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Trang 21(mg)
Surfactant (mg)
Cholesterol (mg)
Chloroform (ml)
Water (ml)
Trang 23Yield point (Pa)
% Permeated (24 h)
Mean zone of inhibition of B Subtilis (mm)*
Control Plecebo CN60-1 CN60-1 Marketed eye
Trang 24Fig 3: Transcorneal permeation profile
Fig 4 In-house bioadhesion testing assembly
Fig 5: Fluorescent images showing permeation through the goat cornea (Dye solution) [(A1) 2 hours, (A2) 6 hours, and (A3) 12 hours], (uncoated niosomes, NS60-5) [(B1) 2 hours, (B2) 6 hours, and (B3) 12 hours], and (coated niosomes CNS60-1) [(C1) 2 hours, (C2) 6 hours, and (C3) 12 hours]
Fig 6: Histological study of goat cornea A KCl solution, B Normal saline, C Drug suspension, and D CNS60-1